They are a barrier to entry, and they are a measure to ensure safety of new cures. It's a tough balance.
They are a barrier to entry, and they are a measure to ensure safety of new cures. It's a tough balance.
It seems to me that the safety aspect is currently very strong, on the expense of long time-to-market and high barrier of entry to market.
That would not mean staying where we are, it would mean starting to slowly go backwards in the tools available for health care (because e.g. some antibiotics are slowly becoming inefficient and new ones should be developed - and currently the world is not doing enough of that.)
See e.g. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2095020/
http://healthland.time.com/2012/09/27/how-to-survive-a-plagu...
https://www.opendemocracy.net/transformation/ray-filar/silen...